Anastrozole
Product Images NDC 45865-909

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 45865-909). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (909)

Anastrozole tablets 1 mg carton label, generic for Arimidex, manufactured by Intas Pharmaceuticals Limited. The label includes directions to take tablets as directed by a physician and displays the NDC 45865-909-30. The packaging indicates white, round, film-coated tablets and includes lot and expiration date information fields.*

FDA Label Image

Figure 1 (Anastrozole Fig1)

A line graph comparing the disease-free survival over time (in months) between two randomized treatments, anastrozole and tamoxifen. The y-axis shows the proportion of patients alive and disease-free, while the x-axis represents time in months up to 96 months. A table below the graph displays the number of patients at risk for both treatments at various time points.*

FDA Label Image

Figure 2 (Anastrozole Fig2)

A Kaplan-Meier survival curve chart showing disease-free survival over time in months comparing two randomized treatments: anastrozole and tamoxifen. The y-axis represents the proportion alive and disease-free, and the x-axis represents time in months up to 80. Patient numbers at risk for each treatment are noted below the x-axis for various months.*

FDA Label Image

Figure 3 (Anastrozole Fig3)

A Kaplan-Meier curve showing the proportion of patients event-free over time (up to 120 months) comparing Anastrozole and Tamoxifen treatments. The x-axis represents time to event in months, and the y-axis shows the event-free proportion. Patient numbers at risk are listed beneath the graph.*

FDA Label Image

Figure 4 (Anastrozole Fig4)

This is a Kaplan-Meier survival curve chart comparing the proportion of patients without an event over time (in months) between two randomized treatments: Anastrozole and Tamoxifen. The x-axis represents time to event in months, and the y-axis shows the proportion event-free. The chart includes numbers of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure 5 (Anastrozole Fig5)

A survival analysis graph depicting time to progression in months for two randomized treatments: Anastrozole and Tamoxifen. The y-axis shows the proportion not progressing, and the x-axis shows time to progression in months up to 32 months. The graph includes stepwise curves for each treatment group and corresponding numbers at risk below the x-axis.*

FDA Label Image

Figure 6 (Anastrozole Fig6)

A line graph comparing the proportion of patients not progressing over time in months for randomized treatments Anastrozole and Tamoxifen. The x-axis represents time in months up to approximately 42 months, and the y-axis represents the proportion not progressing from 0 to 1. Two curves, one solid for Anastrozole and one dashed for Tamoxifen, show progression trends over time.*

FDA Label Image

Chemical Structure For Anastrozole (Anastrozole Str)

Chemical structure of Anastrozole showing its molecular arrangement with aromatic rings and nitrogen-containing groups, illustrating the compound's chemical composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.